



My Infertility

My Pelvic Pain

My Endometriosis?

Introducing

 *My*
Receptiva



Cicero
Diagnostics

The first reliable non-invasive test for the detection of endometriosis for patients with undiagnosed pain and for patients with unexplained infertility.

About The Test

The MyReceptiva™ test is a proven and powerful tool for the detection of endometriosis using a protein marker called BCL6 (B-cell lymphoma 6). The test was developed and patented by researchers at the University of North Carolina at Chapel Hill and originally licensed by Cicero Diagnostics for endometriosis detection in October of 2016.

BCL6 plays a complex role in the pathogenesis of endometriosis, affecting multiple aspects of the disease, including cell growth, survival, inflammation, and immune response. BCL6 is expressed in high levels on the uterine lining in over 90% of the cases in women with endometriosis (both symptomatic and asymptomatic). BCL6 is not typically detected in women with normal endometrial tissue.

Cicero launched the first version of BCL6 testing in 2017 under the brand name ReceptivaDx™. That test is now used by over 450 fertility centers in the US and around the world to assist in identifying previously undetected endometriosis in patients with implantation failure history. Since that launch, various prospective and retrospective studies have demonstrated the sensitivity and specificity of the test to endometriosis, all confirmed by surgical laparoscopy.

The MyReceptiva™ test has been created as an affordable testing option to help women get faster answers for their undiagnosed pelvic and abdominal pain, and to help the 80% of women with fertility issues that cannot afford or are unlikely to pursue advanced fertility assistance and procedures such as IVF.

Testing with Confidence

93%

Sensitivity

96%

Specificity

**Over 35,000 patients
tested since 2017**

**Over 25 peer-reviewed
publications**

For the most updated list of references concerning BCL6, endometriosis detection and treatment outcome studies, visit us online at www.myreceptiva.com

Who Should Consider The MyReceptiva™ Test?

Endometriosis symptoms are frequently non-specific, making diagnosis difficult.

Endometriosis Symptoms

- ✓ Undiagnosed pelvic or abdominal pain.
- ✓ Family history of endometriosis, pelvic or abdominal pain.
- ✓ Pain during sex.
- ✓ Recurrent bladder or bowel pain.
- ✓ High Body Mass Index (BMI) combined with non-specific symptoms such as anxiety, depression or fatigue.

Early diagnosis and treatment can mitigate later complications.

Infertility Issues

- ✓ **Women 34 and under who have failed to conceive after 12 months of trying to conceive naturally.**
- ✓ **Women 35 and over with unexplained infertility after 6 months of trying to conceive naturally.**
- ✓ **Women with one or more consecutive miscarriages during the first 13 weeks of pregnancy.**
- ✓ **Women & families wanting to screen before considering expensive next steps such as IVF.**

For Patients with Undiagnosed Pain

- ✓ The MyReceptiva™ endometrial biopsy analysis has a proven 93% sensitivity & 96% specificity for endometriosis.
- ✓ The test identifies patients with undiagnosed pain that would most benefit from referral to endometriosis surgeon specialists.



Mona Orady MD, FACOG
Gynecologic Surgeon
Director - Orady Women's Clinic

"For years, the women's healthcare field has lacked a test that could assist in triaging patients with undiagnosed pelvic or abdominal pain. The MyReceptiva™ test has proven to be a powerful predictor of endometriosis that can be performed during a routine office visit allowing for expedited referrals to endometriosis specialists for an official diagnosis and a proper treatment plan."

-Mona Orady, M.D.

Chief Medical Advisor, Former President of
the Society of Laparoscopic & Robotic
Surgeons (SLS) and current advisor to SLS.

UNDIAGNOSED ENDOMETRIOSIS IS A GLOBAL PROBLEM

Facts:

- Endometriosis is the second leading cause of hysterectomies in the U.S.
- The average time to an endometriosis diagnosis is 7 to 10 years.
- 65% of women with endometriosis are misdiagnosed with 46% having to see more than 5 doctors before getting an accurate diagnosis.
- Endometriosis affects approximately 10% of women of reproductive age globally.
- Endometriosis is the primary cause of 30 to 50% of infertility in women.
- Endometriosis is the primary cause of 70 to 90% of pelvic pain in women.

For Patients with Unexplained Infertility or Recurrent Pregnancy Loss

- ✓ MyReceptiva™ provides answers and potential treatment pathways for women experiencing unexplained infertility.
- ✓ The test can identify progesterone resistance in women experiencing pregnancy loss in the absence of genetic anomalies.
- ✓ MyReceptiva™ also serves as a potential cost savings tool to identify fertility issues in advance for women, couples & families considering the expensive next steps of IVF or surrogacy.



"The MyReceptiva™ test is an important advancement for women with fertility issues. The results can be life-changing, even for women not currently considering IVF. I've been using BCL6 analysis since 2017 and have helped thousands of women use those results to move forward and start a family.



Dr. Aimee Eyvazzadeh, M.D.
RE and Fertility Specialist

It's my personal mission to offer fertility guidance that is accessible to everyone. My hope is to empower women by making them more aware of their fertility, which allows them to make more informed choices. The MyReceptiva™ test is a tremendous next step."

-Dr. Aimee | www.draaimee.org

Infertility is the third leading disease in the world, and there are over 20 million people in the United States who don't have access to fertility treatment.

Women testing positive for BCL6 are 5x less likely to become pregnant than women testing negative.

Women testing positive for BCL6 now have multiple treatment options with proven success rates to help them in their journey to build a family.

Over 450 fertility centers in the US and around the world have trusted Cicero Diagnostics and BCL6 testing since 2017.

SAMPLE COLLECTION INFORMATION FOR PROVIDERS

Biopsy Timing:

Samples should be collected 7-10 days after ovulation detection. Ovulation and biopsy dates should be noted on enclosed test request form.

Biopsy Description:

Standard endometrial biopsy technique. Optimal sampling is one-half pipelle of endometrial tissue. Adequate sampling is reflected by sample that sinks into 10% formalin vial.



A floating sample indicates excessive mucosa and insufficient endometrial tissue for analysis. Another pass should be attempted

Contraindications:

Patient should not be on birth control.

Patient should wait one complete menstrual cycle before scheduling biopsy to ensure birth control medication won't influence results.

No invasive procedures in the 60 days leading up to the biopsy collection. This includes hysteroscopies and other procedures such as D&Cs.

**Please call us at 800-709-5510
for more information**

Test Request Form:

Please make sure the patient's test request form is fully completed. Clinical history or current pain symptoms, if relevant, should also be noted. Our pathology team will note this history as part of their final case report.

Sample Transport:

All overnight shipping materials and pre-paid stamps have been included to allow for safe and rapid transport to our US based lab. Samples held over due to holidays or weekend schedules are stable at room temperature and do not require special handling.

Communication of Results:

Please provide a fax number on the test request form for results to be communicated. High volume referrers can be provided a portal login to obtain results 24/7 365 days a year. Cicero Diagnostics does not provide results directly to patients.

Turnaround Times for Results:

Results are typically available in 7-10 days.

Result Interpretation & Suggested Treatment Guidelines

Please visit us at www.myreceptiva.com for more information on result interpretations.

Although Cicero Diagnostics, Inc. is not directly involved in the development of treatment guidelines, we work closely with a panel of clinical experts that have developed, published, and shared suggested treatment guidelines for providers and patients.

A listing of qualified endometriosis surgeons is also available for potential patient referrals.

MyReceptiva™ Results

BCL6 results are made available within 7-10 days and reported as either POSITIVE or NEGATIVE. A full pathology report is included at no additional charge. Results are communicated via fax or accessed via our lab portal.

POSITIVE BCL6 RESULT - Indicates that endometriosis is likely to be present and will be found via laparoscopy with greater than 90% probability.

NEGATIVE BCL6 RESULT - A negative result indicates no abnormal inflammation present and a less than 7% likelihood that endometriosis would be found via laparoscopy.

Pricing / Insurance Coverage

The MyReceptiva™ test is offered as a self-pay testing service. Cicero Diagnostics does not bill or contract with insurance.

Providers can instruct their patients to pre-pay online for the MyReceptiva test at www.myreceptiva.com for the price of \$585.00. This will initiate the shipping process of the MyReceptiva™ Collection Kit to be sent to the patient's home address.

Patients will receive a detailed receipt from Cicero Diagnostics with all laboratory CPT codes listed. When coupled with the provider's ICD-10 coding, patients can expect some form of reimbursement based on their individual plan or flexible healthcare spending account. Reimbursements are not guaranteed and will vary by payer.

For healthcare providers that prefer to carry MyReceptiva™ kits in their office, test collection kits can be purchased in quantity at a discounted price.

About Cicero Diagnostics

Cicero Diagnostics was founded to expedite new testing technologies in the women's healthcare sector by shortening the time from the clinical research stage to actual clinical utility. Since 2017, Cicero Diagnostics has been providing testing services to the global fertility community via its ReceptivaDx test. In 2024, the company expanded its current test offering to bring affordable detection testing services to the Ob-Gyn and other women's healthcare professionals to increase access for all women. Cicero Diagnostics has the exclusive license to multiple markers associated with endometriosis detection in addition to their role in unexplained infertility. The company is headquartered in Henderson, Nevada.

For more information concerning MyReceptiva™ testing and the most updated information on treatment protocols and endometriosis surgeon referrals, please visit us at

www.myreceptiva.com

CICERO DIAGNOSTICS, INC. HENDERSON, NV
800-795-5385 | WWW.CICERODX.COM